Stem Cell Treatment Gives Man With MS The Ability To Walk Again

December 14, 2009

Australia (ChattahBox) – A 20-year-old man suffering from multiple sclerosis has made a miraculous recovery due to a new treatment that uses stem cells to target the damaged immune system.

Ben Leahy was diagnosed with MS in 2008. It was a matter of months before he was unable to walk, and he has been struggling against the disease ever since.

But doctors have begun a treatment that is being called a medical miracle in the world of multiple sclerosis. They used his own stem cells, taken from his bone marrow, to transplant back into his body.

“At the moment there’s a good chance we may have arrested the disease,” Dr Colin Andrews was quoted by The Telegraph.

“He walks pretty well, there’s only some mild weakness in his right leg and some visual loss in one eye and apart from that he’s very intact.”

The progress he has made has shown great potential for other patients to be treated using the same method. Doctors hope this could be yet another step towards a cure.

Source


Comments

4 Responses to “Stem Cell Treatment Gives Man With MS The Ability To Walk Again”

  1. Stem Cell Treatment Gives Man Back The Ability To Walk … Treatment Me on December 14th, 2009 11:16 pm

    […] original here: Stem Cell Treatment Gives Man Back The Ability To Walk … By admin | category: treatment | tags: cause-more, done-venting, from-multiple, […]

  2. Residency Requirement for Public Adjusters Unconstitutional … | Insurance Finance Wisdom on December 14th, 2009 11:33 pm

    […] Stem Cell Treatment Gives Man With MS The Ability To Walk Again … […]

  3. Cris Kerr on December 15th, 2009 1:32 am

    I don’t understand… everyone can write about MS treatments that have not
    been proven effective over extended periods of time for all forms of MS,
    yet will not write of treatments that patients themselves say have been
    effective for them over extended periods of time… and importantly, not
    just for Relapsing Remitting MS but also progressive forms of MS and other
    immune system diseases.

    The free ebook ‘Those Who Suffer Much, Know Much’ available from LDN
    Research Trust in the UK contains 29 MS success stories presented as
    patient case studies. The book features a treatment patients themselves say
    is working for them, low doses of naltrexone (LDN)… or in other words,
    extremely low doses of an old drug with a good safety profile but
    unfortunately, unlike stem cells, one that happens to be long
    out-of-patent.

    Understandably, with no profit potential the health industry has expressed
    zero interest in trialling this treatment, but even our health authorities
    are ignoring the potential of this lower cost, lower risk treatment.

    This response may well be deleted as many have been before, but at least
    one more person will now be LDNAware.

    (1) PILOT TRIAL NEWS – 1: Mult Scler. 2008 Sep;14(8):1076-83

    A pilot trial of low-dose naltrexone in primary progressive multiple
    sclerosis.

    Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M,
    Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi
    M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.

    Institute of Experimental Neurology (INSPE) and Department of Neurology,
    San Raffaele Scientific Institute, Via Olgettina 58, Milan, Italy;
    Fondazione Don Carlo Gnocchi, IRCCS, Milan, Italy.

    A sixth month phase II multicenter-pilot trial with a low dose of the
    opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with
    primary progressive multiple sclerosis (PPMS).

    The primary end points were safety and tolerability.

    Secondary outcomes were efficacy on spasticity, pain, fatigue, depression,
    and quality of life. Clinical and biochemical evaluations were serially
    performed. Protein concentration of beta-endorphins (BE) and mRNA levels
    and allelic variants of the mu-opiod receptor gene (OPRM1) were analyzed.

    Five dropouts and two major adverse events occurred. The remaining adverse
    events did not interfere with daily living. Neurological disability
    progressed in only one patient.

    A significant reduction of spasticity was measured at the end of the trial.
    BE concentration increased during the trial, but no association was found
    between OPRM1 variants and improvement of spasticity. Our data clearly
    indicate that LDN is safe and well tolerated in patients with PPMS.

    PMID: 18728058 PubMed – in process
    http://www.ncbi.nlm.nih.gov/pubmed/18728058

  4. GamesThirst – News Gamers Thirst For: Reloaded Review: Dead or … | Water Sports Leisure Knowledge on December 16th, 2009 4:09 pm

    […] Stem Cell Treatment Gives Man With MS The Ability To Walk Again … […]

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.